Definium Therapeutics (NASDAQ:DFTX) CEO Sells $1,315,236.24 in Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the sale, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. The trade was a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Definium Therapeutics Stock Up 0.4%

Shares of NASDAQ DFTX traded up $0.16 during midday trading on Friday, reaching $44.95. The company’s stock had a trading volume of 12,203,314 shares, compared to its average volume of 2,289,586. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $47.01. The stock has a 50 day simple moving average of $24.13 and a 200-day simple moving average of $19.18. The stock has a market capitalization of $4.48 billion, a price-to-earnings ratio of -18.05 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). Equities research analysts predict that Definium Therapeutics, Inc. will post -2.29 earnings per share for the current year.

Institutional Trading of Definium Therapeutics

A number of hedge funds have recently made changes to their positions in DFTX. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Definium Therapeutics during the third quarter worth about $107,000. Flagship Harbor Advisors LLC bought a new stake in Definium Therapeutics in the fourth quarter worth about $117,000. Finally, Caxton Associates LLP purchased a new position in Definium Therapeutics in the third quarter valued at about $126,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DFTX. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a research note on Monday. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday. JonesTrading upped their price objective on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a report on Wednesday. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday. Finally, Needham & Company LLC lifted their target price on shares of Definium Therapeutics from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $47.08.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.